https://www.selleckchem.com/pr....oducts/pf-4708671.ht
Studies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results. This meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients. Published articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio
Like
Comment
Share
